What We're Reading: Vision Loss Gene Therapy; Autism Spectrum Disorders; Dementia in the Hospital
New vision loss gene therapy gets a price tag below the expected $1 million mark; new evidence finds that the prevalence of autism spectrum disorders has plateaued; hospitals are ill-equipped to care for dementia patients, but a new effort could change that.
Vision Loss Gene Therapy Gets a Price
The first gene therapy to treat a hereditary form of vision loss has received a price tag that is just slightly below the expected $1 million price tag.
Autism Spectrum Disorders Prevalence
Evidence from the National Health Interview Survey has found that prevalence of autism spectrum disorders has plateaued. Researchers found that 2.41% of US kids and teenagers had a form of autism between 2014 and 2016,
Hospitals Ill-Equipped to Handle Dementia Patients
For patients with Alzheimer’s disease and other forms of dementia, the chaotic, nosy atmosphere in hospitals can be difficult. However,
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025